PHILADELPHIA — The Abramson Cancer Center (ACC) of the University of Pennsylvania will be presenting nearly 200 abstracts, of which 93 are oral presentations, during the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition at the Georgia World Congress Center in Atlanta. Among research the team will present is the latest findings on the use of chimeric antigen receptor (CAR) immunotherapy, which researchers in the ACC pioneered, leading to the first FDA approval of the therapy in 2017. New studies being presented at ASH evaluated the efficacy of combination CAR T treatment, the impact of a patient’s gut microbiota on CAR T response, and long-term remission associated with CAR T therapy.
SATURDAY, DECEMBER 11
Gut Microbiota Tuning Promotes Tumor-Associated Antigen Cross Presentation and Enhances CAR T Antitumor Effects Clinically Relevant Abstract
Abstract #163, 12 p.m. - 1:30 p.m., B405-B407, Level 4, Building B (Georgia World Congress Center)
Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells
Abstract #166, 12 p.m. - 1:30 p.m., B405-B407, Level 4, Building B (Georgia World Congress Center)
The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies
Abstract #253, 2 p.m. -3:30 p.m., Hall A1 (Georgia World Congress Center)
SUNDAY, DECEMBER 12
CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL
Abstract #469, 12 p.m. - 1:30 p.m., B401-B402, Level 4, Building B (Georgia World Congress Center)
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.